4. Metastatic, castration-resistant

- AOH - PROSELICA - Randomized, open label study comparing Cabazitaxel at 20 mg per m2 and at 25 mg per m2 every 3 weeks in combination with Prednisone for the treatment of mCRPC previously treated with Docetaxel containing Regimen
- CUA - A Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy
- CUA - A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
- CUA - A Multicenter Phase 2, Randomized, Double-Blind, Efficacy and Safety Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer Who Have Failed Primary Androgen Deprivation Therapy
- GUH - A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
- GWU - A Phase 3, Randomized, Double-blind, Controlled Trial of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
- HUH - A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
- JHMI J0874 A Phase I Study of the mTOR Inhibitor Temsirolimus in Combination with the HDAC Inhibitor Vorinostat in Patients with Metastatic Prostate Cancer
- JHMI J0915 Phase I, First in Human Study of Orally Administered AMG 900 in Adult Subjects with Advanced Solid Tumors
- JHMI J1066 A Phase I and IIa Study of Safety and Efficacy of Alpharadin with docetaxel in patients with bone metastases from castration-resistant prostate cancer
- JHMI J1156 Randomized, Open Label Phase 3 Study Comparing Cabazitaxel at 20 mg per m2 and at 25 mg per m2 Every 3 Weeks in Combination with Prednisone for mCRPC Previously Treated with a Docetaxel Containing Regimen
- JHMI J11151 A Phase 3, randomized, double-blind, controlled trial of cabozantinib -XL184- vs. mitoxantrone plus prednisone in men with previously treated symptomatic CRPC
- JHMI J12103 A Randomized Gene Fusion Stratified Phase 2 Trial Of Abiraterone With Or Without ABT-888 For Patients With Metastatic Castration-Resistant Prostate Cancer
- JHMI J12122 A Phase 2, Open-label, Multicenter Study of PSMA ADC in Subjects with Metastatic Castration-resistant Prostate Cancer (mCRPC)
- JHMI J12125 TAXYNERGY Phase II Trial to Evaluate Benefit of Early Switch from first-line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the opposite sequence
- JHMI J1249 A Phase Ib/II Study of GDC-0068 Or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
- NCI 11-C-0262 A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V,F ± GM-CSF in Men with Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer
- NCI 12-C-0079 A Phase II Study of AMG 386 and abiraterone in metastatic castration resistant prostate cancer
- NCI 12-C-0080 NaF PET/CT repeatability, responsiveness & response assessment in mCRPC to bone w/ either docetaxel or AR-directed therapies
- NCI 12-C-0204 Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer
- NCI 13-C-0146 A Randomized Phase II Trial Combining Vaccine Therapy With PROSTVAC/TRICOM and Enzalutamide vs. Enzalutamide Alone in Men With Metastatic Castration Resistant Prostate Cancer
- UMD - A Randomized, Double-Blind, Phase II, Efficacy and Safety Study of MDV3100 Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer
- UMD - A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
- UMD - A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
- UMD - A Phase 2, Open-label, Multicenter Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer
- UMD - Improving Cancer Foci Detection in prostate Cancer Using Multiparametric MRI/MRS and Machine Learning to Better Manage the Disease
- WRNMMC - A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
- WRNMMC - ARMOR2 A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer